Cygnus mulling GlucoWatch sale
This article was originally published in The Gray Sheet
Executive Summary
Non-invasive glucose monitor maker is considering the sale of "some or all" of its assets, among other options, to meet debt obligations and continue operations. The move would follow distributor Sankyo's decision not to honor previous purchase commitments through March 2004, Cygnus says (1"The Gray Sheet" Oct. 13, 2003, p. 17). On Nov. 6, Sankyo countered Cygnus' Oct. 6 breach-of-contract suit, citing defamation and breach of contract and seeking declaratory relief. As of Sept. 30, Cygnus had $9.1 mil. in cash and total liabilities of $81.5 mil. On Nov. 13, the firm reported a Q3 loss of $9.1 mil. on sales of $1.1 mil. (down 31%). Sankyo already has about two years' inventory, "so we anticipate they will continue to [make] the product available for an extended period," Cygnus says...
You may also be interested in...
Sankyo/Cygnus settlement
Sankyo Pharma agrees to pay $30 mil. to dissolve an agreement to distribute Cygnus' GlucoWatch G2 Biographer diabetes monitors in the U.S., companies announce Dec. 23. The settlement requires Sankyo to provide transition services related to product distribution for six months and to give Cygnus the title to its remaining inventory of GlucoWatch products, approximately 20,000 G2 Biographers and 1 mil. AutoSensors.Cygnus had sued Sankyo for breach of contract and laid off 60% of its workforce, following Sankyo's decision to terminate the deal (1"The Gray Sheet" Nov. 17, 2003, In Brief). Cygnus notes it is in discussions with potential distributors...
Cygnus GlucoWatch Distributor Asks For Proof Of Fiscal Stability By Oct. 16
Cygnus alleges it will suffer $450 mil. in damages and lose $1 bil. in potential revenue over the next 12 years if Sankyo Pharma ceases marketing and distribution of its GlucoWatch non-invasive glucose monitor
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.